These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-001997-97 COMPARISON OF 2 CHEMOTHERAPY REGIMENS IN NON SMALL CELL LUNG CANCER PATIENTS RELAPSING AFTER SURGERY AND PERI OPERATIVE CHEMOTHERAPY A RANDOMIZED PHASE III STUDY. 2014-11-12 due-trials
Reported results Terminated 2008-004897-41 A randomized, double-blind, placebo-controlled Phase II-III multi-centre study to evaluate the effect of adjuvant pazopanib (GW786034) versus placebo on post-surgical disease-free survival in patients... 2016-04-01 due-trials
Reported results 2008-004939-38 Essai randomisé de phase II/III évaluant une stratégie thérapeutique post-opératoire individualisée chez les patients opérés d’un carcinome bronchique non à petites cellules (CBNPC) non épidermoïde de... 2015-12-31 due-trials
Reported results 2009-010187-42 Etude de phase II-III randomisée comparant bevacizumab 7,5 mg/kg en association avec la chimiothérapie versus la chimiothérapie seule dans les cancers bronchiques à petites cellules étendus et chimios... 2013-07-26 due-trials
Reported results 2009-012412-41 Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules ... 2015-12-31 due-trials
Reported results 2010-023676-48 Phase II trial evaluating the efficacy and safety of carboplatin plus pemetrexed in Human Immunodeficiency Virus positive (HIV+) patients with stage III (not amenable to radiation or inoperable) or st... 2017-07-03 due-trials
Reported results 2011-003571-11 A randomised, phase II trial to evaluate a treatment with Tyrosine Kinase Inhibitor of Epidermal Growth Factor (EGFR-TKI) versus EGFR-TKI associated with an anti-estrogen treatment (fulvestrant) in wo... 2018-11-30 due-trials
Reported results 2012-000092-16 Phase III study evaluating two strategies of maintenance, one with pemetrexed in continuous strategy and one according to the response of induction chemotherapy, in non squamous non small cell lung ca... 2017-11-30 due-trials
Reported results 2012-002647-18 phase II study evaluating the interest of the re-introduction of pemetrexed and platinum (cisplatin or carboplatin) with prolonged angiogenic blocking by bevacizumab in non squamous non small cell lun... 2017-10-13 due-trials
Reported results 2012-004524-38 Phase III study comparing the efficacy of paclitaxel-bevacizumab with docetaxel in 2nd or 3rd line of treatment of non squamous Non Small Cells Lung Cancer 2017-04-12 due-trials
Ongoing, reported early 2012-005520-15 Phase III study comparing maintenance by pemetrexed or gemcitabine to surveillance in elderly patient (≥ 70 year old) with advanced Non Small Cell Lung Cancer controlled by induction chemotherapy not-yet-due
Ongoing 2013-001494-24 A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I Non-Squamous Non-Small Cell Lung Cancer Identified as High Risk by the Pervenio? Lung RS Assay E... not-yet-due
Reported results 2015-003390-15 Phase II study evaluating the combination of cetuximab with afatinib as first-line treatment for patients with EGFR mutated Non Small Cell Lung Cancer Etude de phase II évaluant l’association de ce... 2020-05-30 due-trials
Reported results 2015-004475-75 A randomized phase II study evaluating efficacy and safety of 2nd or 3rd line treatment by Nivolumab monotherapy or Nivolumab plus Ipilimumab, for unresectable Malignant Pleural Mesothelioma (MPM) pat... 2019-06-22 due-trials
Ongoing, reported early 2016-001849-15 A PHASE II PROSPECTIVE IMMUNE NEOADJUVANT THERAPY STUDY OF DURVALUMAB (MEDI4736) IN EARLY STAGE NON-SMALL CELL LUNG CANCER Etude de phase II évaluant une immunothérapie néoadjuvante, le durvalumab,... not-yet-due
Reported results 2016-003795-49 A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer... 2020-12-01 due-trials
Reported results 2016-003796-22 Immunotherapy by Nivolumab after prior Chemotherapy for HIV+ patients with Advanced non-small cell lung cancer (NSCLC): IFCT-CHIVA2 phase IIa trial 2021-02-18 due-trials
Other 2017-002540-33 A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with PDL1-positive stage IV Non-Small Cell... not-yet-due
Ongoing 2017-002561-21 Randomised Open Label Adaptive Phase III trial of addition of Belinostat to chemotherapy in patients with locally advanced potentially resectable Thymic Epithelial Tumors (TET) not-yet-due
Completed, report not yet due 2018-003506-11 Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel 2023-12-18 not-yet-due
Ongoing 2018-004742-42 A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumo... not-yet-due
Ongoing 2019-002230-37 A phase II non-randomized, single group assignment, open-label, multicenter study of efficacy and safety of lORlatinib (PF-06463922) monotherapy after failure of first-line second-generation ALK kinas... not-yet-due
Ongoing 2019-002805-23 A Phase II, multi-centre study, to evaluate the efficacy and safety of osimertinib treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC) with Brain or Leptomeningeal metastases not-yet-due
Ongoing 2019-004621-24 A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer not-yet-due
Ongoing 2020-004466-19 A phase II single-group assignment, multicenter study of efficacy and safety of lorlatinib monotherapy after failure of first-line tyrosine kinase inhibitor in patients with advanced ROS1-positive non... not-yet-due
Other 2021-002567-22 A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patient... not-yet-due
Ongoing 2021-006044-27 A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembr... not-yet-due